Evidence map›Paper›PMID 36134611›Full record

ArticleThe Journal of infectious diseases2022

Restoration of Neutralization Activity Against Omicron BA.2 and BA.5 in Older Adults and Individuals With Risk Factors Following the Fourth Dose of Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Vaccine.

Masayuki Amano, Sachiko Otsu, Yasuko Ichikawa, Nobuyo Higashi-Kuwata, Shuzo Matsushita, Shinya Shimada, Hiroaki Mitsuya

Open access · hybridAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Masayuki AmanoDepartment of Clinical Retrovirology, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.ORCID 0000-0003-0516-9502
Sachiko OtsuDepartment of Clinical Retrovirology, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Yasuko IchikawaKumamoto Ganeral Hospital, Japan Community Health Care Organization, Kumamoto, Japan.
Nobuyo Higashi-KuwataDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Shuzo MatsushitaDepartment of Clinical Retrovirology, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Shinya ShimadaKumamoto Ganeral Hospital, Japan Community Health Care Organization, Kumamoto, Japan.
Hiroaki MitsuyaDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Kumamoto University · JPNational Center for Global Health and Medicine · JP

Funding

NCI NIH HHS
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BNT162 VaccineCOVID-19AgedAntibodies, NeutralizingAntibodies, ViralHumansRisk FactorsSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralBNT162 Vaccine

Identifiers

PMID36134611
PMCPMC9619461
OpenAlexW4296816614

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.